Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Autor: Teipel, Stefan J, Cavedo, Enrica, Hampel, Harald, Group, Hippocampus Study, Godefroy, O., Deramond, H., Etcharry Bouyx, F., Pasco Papon, A., Dartigues, Jf, Allard, M., Rouaud, O., Ricolfi, F., Grothe, Michel J, Moreaud, O., Krainik, A., Pasquier, F., Bomboi, S., Delmaire, C., Couratier, P., Maubon, A., Vighetto, A., Croisile, B., Louis-Tisserand, G., Lista, Simone, Ceccaldi, M., Girard, N., Michel, B., Peretti, Mp, Touchon, J., Bonafe, A., Benetos, A., Barroche, G., Bracard, S., Vercelletto, M., Galluzzi, Samantha, Calvier Auffray, E., Robert, P., Chanalet, S., Dubois, B., Hampel, H., Dormont, D., Lehericy, S., Hugon, J., Pancrazi, M. P., Reizine, D., Colliot, Olivier, Gil, R., Vandermarcq, P., Novella, J. L., Pierot, L., Belliard, S., Carsin, M., Martinaud, O., Gerardin, E., Laurent, B., Barral, Fg, Chupin, Marie, Sellal, F., Ousset, Pj, Puel, M., Ait Ameur, A., Dumas, H., Mondon, K., Cottier, Jp, Bakardjian, Hovagim, Dormont, Didier, Dubois, Bruno

Publikováno v: Neuropharmacology
Neuropharmacology, Elsevier, 2016, 108, pp.128-35
Neuropharmacology, 2016, 108, pp.128-35. ⟨10.1016/j.neuropharm.2016.02.005⟩
Neuropharmacology 108, 128-135 (2016). doi:10.1016/j.neuropharm.2016.02.005
HAL

International audience; We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (Franc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048652cedc13c91d1495b2af6a8ae64f
https://hal.inria.fr/hal-01372417